AACR 2024 | Ascentage Pharma Mempersembahkan Hasil dari Tiga Studi di Pertemuan Tahunan Asosiasi Kanker Amerika 2024 oleh Investing.com
At the 2024 American Association of Cancer Research Annual Meeting (AACR 2024), Ascentage Pharma (6855.HK) made a significant announcement regarding the latest results from three preclinical studies of their novel drug candidates. The studies focused on olverembatinib, MDM2-p53 inhibitor alrizomadlin (R&D Code: APG-115), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development (EED) inhibitor APG-5918. … Baca Selengkapnya